The study drug is a potential new treatment for advanced solid tumours with a specific gene alteration.
Some patients become resistant to the currently available treatments for these advanced solid tumours. This study drug is expected to be effective even in patients who have developed this resistance. It is not a chemotherapy drug.
The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.
Call us on 1800 243 733 to discuss your eligibility today!